PIK3CA and neoplasm: Aside from the direct anti-proliferative effect on tumor cells, increasing evidence supports the immune-modulatory effect of PI3K/AKT/mTOR and MAPK/MEK/ERK inhibitors, making their adjuvant potential with immunotherapy an intriguing therapeutic option.